Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00961
|
|||||
| Drug Name |
Flucloxacillin
|
|||||
| Synonyms |
(2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S(2alpha,5alpha,6beta)); 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido]-2,2-dimethylpenam-3alpha-carboxylic acid; BRL 2039; FLOXACILLIN; Flopen (TN); Floxacillin (USAN); Floxacillin [USAN]; Floxapen; Floxapen (TN); Fluclox; Flucloxacilina; Flucloxacilina [INN-Spanish]; Flucloxacillin (INN); Flucloxacillin sodium; Flucloxacillin-Sodium; Flucloxacilline; Flucloxacilline [INN-French]; Flucloxacillinum; Flucloxacillinum [INN-Latin]; Fluorochloroxacillin; MFIPC; Rel-(2R,6S)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylato
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bacterial infections [ICD11: 1A00-1H0Z] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H17ClFN3O5S
|
|||||
| Canonical SMILES |
CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O
|
|||||
| InChI |
InChI=1S/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
|
|||||
| InChIKey |
UIOFUWFRIANQPC-JKIFEVAISA-N
|
|||||
| CAS Number |
CAS 5250-39-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 453.9 | Topological Polar Surface Area | 138 | ||
| Heavy Atom Count | 30 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
2.6
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:5098
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | Drug information of Flucloxacillin, 2008. eduDrugs. | |||||
| 2 | Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.